news
-
27 July 2020Axonics® Announces 2-Year Topline Clinical Results from ARTISAN-SNM Pivotal Study
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced completion of 2-year follow-ups and topline clinical results from its ARTISAN-SNM pivotal study that was conducted to evaluate the safety and efficacy of the Axonics r-SNM System®.
The 2-year study results demonstrate that patients implanted with the Axonics r-SNM System continue to receive clinically meaningful and statistically significant improvements in urinary urgency incontinence symptoms and quality of life. At 2 years, 88% of all implanted patients were therapy responders, consistent with the 89% therapy responder rate reported at 1-year. Eighty percent of patients achieved >75% improvement, with 37% being completely dry. There were no serious adverse or unanticipated device related events.
“The responder rate from the ARTISAN-SNM study continues to be the highest success rate reported in SNM literature and confirms sustained efficacy,” said Karen Noblett, M.D., a board-certified urogynecologist and chief medical officer of Axonics. “Americans with urgency incontinence are undertreated and struggle to find long-term relief. The persistent robust response and patient satisfaction with the Axonics r-SNM System demonstrates that there is an easy to use, highly efficacious treatment available to those suffering from this condition.”
Due to COVID-19, upcoming medical meetings and conferences have been cancelled or restricted to virtual meetings. Detailed study results will be presented to interested parties by study investigators via an Axonics-hosted webinar to be announced in the coming weeks.
ARTISAN-SNM study
The ARTISAN-SNM study is a 129-patient single-arm, prospective, multi-center, unblinded pivotal clinical study to evaluate the safety and efficacy of the Axonics r-SNM System. The study was conducted in 14 centers in the U.S. and five centers in Western Europe. All patients diagnosed with urinary urge incontinence were implanted with a tined lead and the Axonics miniaturized rechargeable neurostimulator in a non-staged procedure. Efficacy data was collected using a 3-day bladder diary, a validated quality of life questionnaire (ICIQ-OABqol), and a subject satisfaction questionnaire. Therapy responders at follow-up were identified as patients with at least a 50% reduction in urinary urgency incontinence episodes compared to baseline. Completion of 2-year follow-ups concludes the ARTISAN-SNM study.
Related
Axonics® Reports Preliminary Second Quarter 2020 Revenue
Axonics® Receives FDA Approval for 3T Full-Body MRI Scans
Axonics® Reports First Quarter 2020 Results
Axonics® Announces Fourth Quarter and Fiscal 2019 Financial Results
Axonics® Sacral Neuromodulation System Receives Reimbursement Approval in Germany
Axonics® Announces FDA Approval of Enhanced Neurostimulator Programmer
Axonics® Announces Preliminary Fourth Quarter and Full Year 2019 Revenue
Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Sanford Health Now Implanting Axonics® Sacral Neuromodulation Systems
Axonics® Announces Pricing of Public Offering of Common Stock
Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System
Axonics® Announces Second Quarter 2019 Financial Results and Operational Update
Axonics® Announces 1-Year Top-Line Clinical Results from its ARTISAN-SNM Pivotal Study
Axonics® Announces Publication of ARTISAN Clinical Study Results in the Journal of Urology
Axonics® Announces First Quarter 2019 Financial Results and Operational Update
Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update
Axonics® Announces Positive Top-Line Clinical Data from its ARTISAN-SNM Pivotal Study
Axonics® Announces Publication of NICE Briefing
Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Axonics® Receives Health Canada Approval for its Sacral Neuromodulation External Trial System
Axonics® Announces Closing of Initial Public Offering of Common Stock
Axonics Modulation Technologies, Inc. Announces Pricing of Initial Public Offering of Common Stock
Axonics® Receives Technology Innovation Award from Medtech Insight
Axonics® Receives CE Mark for its Sacral Neuromodulation External Trial System
Axonics® Completes Enrollment of U.S. FDA Pivotal Study for its Sacral Neuromodulation System
Axonics Announces $40 Million Financing
Axonics® Sacral Neuromodulation System Receives Marketing Approval in Australia
Axonics® Granted Seven New U.S. Patents Related to its Implantable Sacral Neuromodulation Technology
Axonics® Appoints Dr. Karen L. Noblett as Chief Medical Officer
Axonics Announces $20.5 Million Second Closing of its Series C Financing
Axonics Announces $14.5 Million First Close of Series C Financing
Axonics Granted Four U.S. Patents Related to its Implantable Sacral Neuromodulation Technology
Axonics Sacral Neuromodulation System Receives Marketing Approval from Health Canada
Axonics Granted New U.S. Patent Related to its Implantable Neuromodulation Technology
Axonics Sacral Neuromodulation System™ Receives MRI Conditional Labeling
Axonics Announces First Patients Treated in Sacral Neuromodulation Study
Axonics Granted Six U.S. Patents Related to its Implantable Neuromodulation Technology
Axonics Modulation Technologies Announces $38.5 Million Series B Financing